Drug Trial Radar · NCT01058018
Clinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery Disease
Last checked: Nov 19, 2026Latest source record: Apr 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
299
Actual
Start
Dec 2009
Primary completion
Jun 2010
Study completion Sep 2010
Sponsor
- Lead sponsor
- Resverlogix CorpIndustry
- Sponsor type
- Industry
- First posted
- Jan 28, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate dose range, safety and efficacy of RVX000222 in subjects with stable coronary artery disease.
Conditions
- Atherosclerosis
- Coronary Artery Disease
Interventions
RVX000222Drug
RVX000222 twice a day for 12 weeks
PlaceboDrug
Placebo twice a day for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- The percent change in ApoA1 from baseline to 12 weeks post-randomization for each treatment arm compared to placebo.Time frame: from baseline to 12 weeks post-study drug treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Orange County Research Center
Tustin, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.